INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
- 143
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HUTCHMED (China) Limited (“HUTCHMED” or “the Company”) (NASDAQ: HCM) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. HUTCHMED announced on May 2, 2022, that the FDA had rejected the Company’s application for surufatinib to treat certain neuroendocrine tumors. According to the FDA, the Company’s application did not support approval and did not include the required multi-regional clinical trial. Based on this news, HUTCHMED ADSs fell by 18% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005334/en/
